首页/数据集/Ipilimumab and nivolumab first-line therapy in BRAF-mutated metastatic melanoma patients is protective for the occurrence of new brain metastasis.

Ipilimumab and nivolumab first-line therapy in BRAF-mutated metastatic melanoma patients is protective for the occurrence of new brain metastasis.

Zenodo2024-02-06 更新2026-04-07 收录

黑色素瘤免疫治疗

脑转移预防疗效

数据链接：

https://zenodo.org/doi/10.5281/zenodo.10623983 数据链接链接失效反馈

官方服务：

资源简介：

5-years OS, TPFS, BMFS, SABM and biomakers of SECOMBIT trial.

应用场景：

创建时间：

2024-02-06

黑色素瘤免疫治疗

基因表达生物标志物

Tumor samples were obtained from patients with metastatic melanoma before treatment with checkpoint inhibitors. Overall design: melanoma tumor samples from patients treated with checkpoint inhibitors

NIAID Data Ecosystem40

DataSheet_2_The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma.pdf

黑色素瘤免疫治疗

基因突变预测

BackgroundMAP2K1/2 genes are mutated in approximately 8% of melanoma patients; however, the impact of MAP2K1/2 gene alterations on the efficiency of immunotherapy has not been clarified. This study fo

NIAID Data Ecosystem20

PBMCs from stage IV melanoma patients after vaccination with melanoma-targeted mature dendritic cells (mDCs).

黑色素瘤免疫治疗

细胞免疫疗法评估

PBMCs from stage IV melanoma patients after vaccination with melanoma-targeted mature dendritic cells (mDCs).

ChEBI2017-06-01 更新10

Whole Exome Sequening of B16F10 melanoma mouse model for ATLAS identification.

肿瘤新抗原

黑色素瘤免疫治疗

The ATLAS bioassay was developed to empirically identify neoantigens by expressing each unique patient-specific tumor mutation individually in E. coli, pulsing autologous dendritic cells in an ordered

NIAID Data Ecosystem30

Gut microbiome impacts response to PD-1 immunotherapy in melanoma patients

肠道微生物组与免疫治疗反应

黑色素瘤免疫治疗

Pre-clinical mouse models have suggested that the gut microbiome modulates tumor response to checkpoint blockade immunotherapy, however this has not been well-characterized in human cancer patients. H

NIAID Data Ecosystem10

Ipilimumab and nivolumab first-line therapy in BRAF-mutated metastatic melanoma patients is protective for the occurrence of new brain metastasis.

资源简介：

相关数据集